New Comment Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease www.thelancet.com/journals/lan...

📅 @phoebedownes.bsky.social will be attending ID Week, #IDWeek (19-22 October) in Atlanta, GA on behalf of The Lancet Infectious Diseases! 📧Feel free to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BL6Th0

Richard Horton's latest Offline: The unavoidable reckoning tinyurl.com/3b7h5729

New Editorial: More data needed on the FDA's decision to suspend Ixchiq www.thelancet.com/journals/lan...

New comment: What can be learnt from the world's first national vaccination programme against gonorrhoea www.thelancet.com/journals/lan...

New Comment: Malaria resurgence in Africa: confronting the challenges www.thelancet.com/journals/lan...

New Series- Prevention and Management of Infections in People who are Immunocompromised. Two papers on the prevention and management of infections in people who are immunocompromised, a group often neglected in research efforts and so frequently missing from the pages of our journal.

New Comment Multidrug-resistant bacteria amid health-system collapse in Gaza www.thelancet.com/journals/lan...

New Research: Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial www.thelancet.com/journals/lan...

New reserach Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial www.thelancet.com/journals/lan...

Important reporting from my NPR colleagues on the human impacts of the cuts to U.S. foreign assistance. They share the story of twelve people - including kids - who have run out of HIV drugs in Zambia.

New research: Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial www.thelancet.com/journals/lan...

New research: Rates of infection with other pathogens after a positive COVID-19 test versus a negative test in US veterans (November, 2021, to December, 2023): a retrospective cohort study www.thelancet.com/journals/lan...

New editorial: Facts and myths about measles www.thelancet.com/journals/lan...

New series on Zika virus, together with @lancetmicrobe.bsky.social 4 papers on priorities for prepardeness and response www.thelancet.com/series/zika-...